ARGENX SE
ARGXNasdaq
$860.55
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +48.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.
- CEO
- Tim v. Hauwermeiren
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 650
- Website
- argenx.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 13, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.